Skip to main content
OpenTrials
Completed

NCT Number: NCT01681355

Gastrointestinal Tolerance Study of a New Infant Formula

This study is initiated to investigate the gastrointestinal tolerance of a new infant formula in healthy, term, Asian infants.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

Up to 17 week

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Panembahan Senopati Distric Hospital, Bantul, DIY Yogyakarta, Indonesia

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy, well-nourished, term, Asian infants (gestational age ≥ 37 1/7 and ≤ 41 6/7 weeks)
  • The mother had unequivocally decided not to exclusively breast-feed
  • Formula fed for at least one week, receiving at least two formula feedings per day
  • Birth weight appropriate for gestational age (AGA), 2500-4000g
  • Written informed consent from parent(s) and/or legal guardian, aged ≥ 18 years.

Exclusion criteria

  • Age > 17 weeks
  • Infants known to have current or previous illnesses/conditions or intervention which could interfere with the study (impacting tolerance and/or growth), such as gastrointestinal malformations, chronic diarrhoea, malabsorptive syndrome, malnutrition, congenital immunodeficiency, or major surgery, as per investigator's clinical judgement
  • Infants who suffered from gastroenteritis or diarrhoea in the last 4 weeks preceding study start.
  • Infants who used any medication or nutritional supplements (except for vitamin supplementation to complement breastfeeding) in the 4 weeks preceding study start.
  • Infants who have medical conditions for which a special diet other than standard (non hydrolysed) cow's milk-based infant formula is required (such as cow's milk allergy, soy protein allergy, fish protein allergy, egg protein allergy, lactose intolerance, galactosemia).
  • Infants with any history of or current participation in any other study involving investigational or marketed products.
  • Investigator's uncertainty about the willingness or ability of the parents to comply with the protocol requirements.

Treatment and study plan

Infant Formula

Other

Standard cow's milk based infant formula with added prebiotic oligosaccharides, and a modified fat blend and protein composition

Primary outcomes

  1. Gastrointestinal tolerance

    Time frame: up to Week 6

    Gastrointestinal tolerance is measured by stool consistency and gastrointestinal symptoms.

Other outcomes

  1. Anthropometry

    Time frame: Week 3, Week 6

  2. Use of medication and nutritional supplements

    Time frame: Week 1, Week 3, Week 6 and Week 8

  3. Number, type and severity of (serious) adverse events

    Time frame: Week 1, Week 3, Week 6 and Week 8

Sponsors and collaborators

Lead sponsor

Danone Asia Pacific Holdings Pte, Ltd.

Industry

Registry information

Official study title

Open-label Study to Evaluate the Gastrointestinal Tolerance of a New Infant Formula in Healthy, Term, Asian Infants

Acronym: BOOGIE

Important dates

Study start
2012
Primary completion
2012
Study completion
2012
First posted
Sep 7, 2012
Registry last updated
Jan 9, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.